Eric Benevich Sells 19,818 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00.

Neurocrine Biosciences Trading Down 0.4 %

NBIX stock opened at $132.00 on Friday. The firm’s 50-day moving average is $136.15 and its two-hundred day moving average is $126.99. The company has a market capitalization of $13.14 billion, a price-to-earnings ratio of 54.55 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.88 earnings per share. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on NBIX shares. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Citigroup cut their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Barclays raised their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $139.67.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently modified their holdings of NBIX. Mather Group LLC. acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at about $26,000. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth approximately $27,000. Headinvest LLC acquired a new stake in Neurocrine Biosciences during the third quarter valued at approximately $28,000. Lindbrook Capital LLC boosted its holdings in Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Finally, EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences in the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.